Psychedelics

Psyence Biomedical Secures Extension To Meet Nasdaq Compliance Standards

DEA's Case For Scheduling Psychedelics Challenged In Landmark Hearing

Tryptamine Therapeutics Advances Psilocin-Based IV Infusion To Phase 2 Clinical Trials

DEA's Case For Scheduling Psychedelics Challenged In Landmark Hearing

Tryptamine Therapeutics Advances Psilocin-Based IV Infusion To Phase 2 Clinical Trials

Ispire And IKE Tech Advance FDA-Backed Age Verification Tech To Curb Youth Vaping

Healthcare Workers Back Psychedelics But Lack Crucial Knowledge, Study Finds

Ispire And IKE Tech Advance FDA-Backed Age Verification Tech To Curb Youth Vaping

Healthcare Workers Back Psychedelics But Lack Crucial Knowledge, Study Finds

Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders

Medical Cannabis And Legal Cocaine: The Unusual Permit That Puts Border Laws In Check

Psychedelics Recent News

Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

Numinus Wellness sells U.S. clinics to Stella for $3.5M, in a partnership to develop tech-driven solutions for mental health providers.

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Doug Collins' nomination to lead the VA raises questions about how he might handle medical cannabis and psychedelics policies.

New Study Charts Adverse Events In Psychedelic-Assisted Therapies

New framework introduces comprehensive guidelines for assessing side effects in psychedelic-assisted therapies, aiming to enhance safety and patient care.

Mike Tyson On Psychedelics: 'The Toad Showed Me God, And It Changed My Life'

Mike Tyson shares how 5-MeO-DMT helped him find peace, confront fears, and embrace a new perspective on life.

FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory hurdles.

AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?

AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care.

High Tide Closes Final Tranche Of $15M Debt, Plans Retail Growth

High Tide Inc. closes final tranche of $15M debt facility, enhancing financial strength for retail expansion and debt repayment.

Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth

Atai Life Sciences reports Q3 results, highlighting FDA clearance for DMT film, upcoming MDMA trials, and a strong cash position.

Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression

Cybin starts Phase 3 trials for its depression treatment, CYB003, backed by strong Phase 2 data and a solid cash position.

DEA Faces Lawsuit Alleging Bias In Marijuana Rescheduling Process

Researcher David Heldreth sues DEA over alleged legal violations in marijuana rescheduling, citing bias and exclusion of small businesses and Native American tribes.

Patents Reveal New Prodrugs For Psilocin, Promising Reliable Mental Health Treatments

Recent patents on novel psychedelic prodrugs show promise in enhancing stability and efficacy, offering new hope for effective mental health treatments.

Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal

Enveric licenses EB-002 to MycoMedica for neuropsychiatric treatment, focusing on EB-003's development with potential milestones up to $62M.